

Imunoterapie karcinomu prostaty a močového měchýře

THOMAS H. TOTTERMAN, ANGELICA LOSKOG a MAGNUS ESSAND

Clinical Immunology Division, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden

LITERATURA

- 1 **Pardoll D.** Does the immune system see tumors as foreign or self? *Annu Rev Immunol* 2003; **21**: 807–39
- 2 **Sakaguchi S.** Naturally arising CD4⁺ regulatory T cells for immunologic selftolerance and negative control of immune responses. *Annu Rev Immunol* 2004; **22**: 531–62
- 3 **Wang HY, Lee DA, Peng G et al.** Tumorspecific human CD4⁺ regulatory T cells and their ligands: implications for immunotherapy. *Immunity* 2004; **20**: 107–18
- 4 **Dudley ME, Wunderlich JR, Yang JC et al.** Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 2005; **23**: 2346–57
- 5 **Rao PE, Petrone AL, Ponath PD.** Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF- β . *J Immunol* 2005; **174**: 1446–55
- 6 **Walker PR, Saas P, Dietrich PY.** Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. *J Immunol* 1997; **158**: 4521–4
- 7 **Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ.** Dendritic cell immunotherapy: mapping the way. *Nat Med* 2004; **10**: 475–80
- 8 **Ridgway D.** The first 1000 dendritic cell vaccines. *Cancer Invest* 2003; **21**: 873–86
- 9 **Klinman DM.** Immunotherapeutic uses of CpG oligodeoxynucleotides. *Nat Rev Immunol* 2004; **4**: 249–58
- 10 **Davila E, Kennedy R, Celis E.** Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. *Cancer Res* 2003; **63**: 3281–8
- 11 **Ninalga C, Loskog A, Klevenfeldt M, Essand M, Totterman TH.** CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. *J Immunother* 2005; **28**: 20–7
- 12 **Niethammer AG, Xiang R, Ruehlmann JM et al.** Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. *Cancer Res* 2001; **61**: 6178–84
- 13 **Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ.** CD40/CD154 interactions at the interface of tolerance and immunity. *Annu Rev Immunol* 2004; **22**: 307–28
- 14 **Loskog A, Dzojic H, Vikman S et al.** Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. *J Immunol* 2004; **172**: 7200–5
- 15 **Yee C, Thompson JA, Roche P et al.** Melanocyte destruction after antigenspecific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. *J Exp Med* 2000; **192**: 1637–44
- 16 **Dudley ME, Rosenberg SA.** Adoptivecell-transfer therapy for the treatment of patients with cancer. *Nat Rev Cancer* 2003; **3**: 666–75
- 17 **Ghiringhelli F, Larmonier N, Schmitt E et al.** CD4⁺ CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. *Eur J Immunol* 2004; **34**: 336–44
- 18 **Antony PA, Piccirillo CA, Akpınarlı A et al.** CD8⁺ T cell immunity against a tumor/self-antigen is augmented by CD4⁺ T helper cells and hindered by naturally occurring T regulatory cells. *J Immunol* 2005; **174**: 2591–601
- 19 **Jemal A, Murray T, Ward E et al.** Cancer statistics, 2005. *CA Cancer J Clin* 2005; **55**: 10–30
- 20 **Jani AB, Hellman S.** Early prostate cancer: clinical decision-making. *Lancet* 2003; **361**: 1045–53
- 21 **Scattoni V, Montorsi F, Picchio M et al.** Diagnosis of local recurrence after radical prostatectomy. *BJU Int* 2004; **93**: 680–8
- 22 **Petrylak DP, Tangen CM, Hussain MH et al.** Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004; **351**: 1513–20
- 23 **Tannock IF, de Wit R, Berry WR et al.** Docetaxel plus prednisone or mitoxantrone

- plus prednisone for advanced prostate cancer. *N Engl J Med* 2004; **351**: 1502–12
- 24 **Vesalainen S, Lipponen P, Talja M, Syrjanen K.** Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. *Eur J Cancer* 1994; **30A**: 1797–803
- 25 **Essand M.** Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies. *Acta Oncologica* 2005; in press
- 26 **Kobayashi H, Nagato T, Oikawa K et al.** Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. *Clin Cancer Res* 2005; **11**: 3869–78
- 27 **Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A.** Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. *Prostate* 1996; **29**: 371–80
- 28 **Tjoa BA, Erickson SJ, Bowes VA et al.** Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. *Prostate* 1997; **32**: 272–8
- 29 **Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML.** Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. *Cancer Res* 2000; **60**: 829–33
- 30 **Burch PA, Breen JK, Buckner JC et al.** Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. *Clin Cancer Res* 2000; **6**: 2175–82
- 31 **Small EJ, Fratesi P, Reese DM et al.** Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. *J Clin Oncol* 2000; **18**: 3894–903
- 32 **Fong L, Brockstedt D, Benike C et al.** Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. *J Immunol* 2001; **167**: 7150–6
- 33 **Heiser A, Coleman D, Dannull J et al.** Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest* 2002; **109**: 409–17
- 34 **Barrou B, Benoit G, Ouldkaci M et al.** Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. *Cancer Immunol Immunother* 2004; **53**: 453–60
- 35 **Vonderheide RH, Domchek SM, Schultze JL et al.** Vaccination of cancer patients against telomerase induces functional antitumor CD8 T lymphocytes. *Clin Cancer Res* 2004; **10**: 828–39
- 36 **Burch PA, Croghan GA, Gastineau DA et al.** Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. *Prostate* 2004; **60**: 197–204
- 37 **Schellhammer PF, Hershberg RM.** Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. *World J Urol* 2005; in press
- 38 **Essand M, Vasmatis G, Brinkmann U, Duray P, Lee B, Pastan I.** High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. *Proc Natl Acad Sci USA* 1999; **96**: 9287–92
- 39 **Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I.** TARP. A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. *Proc Natl Acad Sci USA* 2000; **97**: 9437–42
- 40 **Carlsson B, Totterman TH, Essand M.** Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. *Prostate* 2004; **61**: 161–70
- 41 **Schumacher TN.** T-cell-receptor gene therapy. *Nat Rev Immunol* 2002; **2**: 512–9
- 42 **Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP.** Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. *Prostate* 2004; **61**: 12–25
- 43 **Patard JJ, Brasseur F, Gil-Diez S et al.** Expression of MAGE genes in transitional cell carcinomas of the urinary bladder. *Int J Cancer* 1995; **64**: 60–4
- 44 **Bahrenberg G, Brauers A, Joost HG, Jakse G.** Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. *Biochem Biophys Res Commun* 2000; **275**: 783–8
- 45 **Ozen H.** Bladder cancer. *Curr Opin Oncol* 1998; **10**: 273–8
- 46 **Sharma P, Gnjatic S, Jungbluth AA et al.** Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. *Cancer Immun* 2003; **3**: 19
- 47 **Konety BR, Nguyen TS, Brenes G et al.** Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. *J Urol* 2000; **164**: 634–9
- 48 **Alexandroff AB, Jackson AM, O'Donnell MA, James K.** BCG immunotherapy of bladder cancer: 20 years on. *Lancet* 1999; **353**: 1689–94

- 49 **Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ.** T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. *J Urol* 1993; **150**: 1018–23
- 50 **Nadler R, Luo Y, Zhao W et al.** Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) mediated antitumor activity. *Clin Exp Immunol* 2003; **131**: 206–16
- 51 **Brandau S, Riemensberger J, Jacobsen M et al.** NK cells are essential for effective BCG immunotherapy. *Int J Cancer* 2001; **92**: 697–702
- 52 **Ponticelli A, Perna F, Maione S et al.** Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG. a model to study tuberculosis immunity. *Respir Med* 2004; **98**: 509–14
- 53 **Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML.** Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. *J Immunother* 2003; **26**: 343–8
- 54 **Perabo FG, Muller SC.** Current and new strategies in immunotherapy for superficial bladder cancer. *Urology* 2004; **64**: 409–21
- 55 **Giannopoulos A, Constantinides C, Fokaeas E et al.** The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. *Clin Cancer Res* 2003; **9**: 5550–8
- 56 **Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA.** IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving *Mycobacterium bovis* bacillus Calmette-Guerin immunotherapy. *J Immunol* 1999; **162**: 2399–405
- 57 **Mohanty NK, Malhotra V, Nayak RL, Arora RP.** Combined low-dose intravesical immunotherapy (BCG interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year followup. *J Chemother* 2002; **14**: 194–7
- 58 **Sarosdy MF, Lowe BA, Schellhammer PF et al.** Oral bropriramine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. *Urology* 1996; **48**: 21–7
- 59 **Malmberg KJ.** Effective immunotherapy against cancer. a question of overcoming immune suppression and immune escape? *Cancer Immunol Immunother* 2004; **53**: 879–92
- 60 **Kastelan Z, Lukac J, Derezić D et al.** Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. *Anticancer Res* 2003; **23**: 5185–9
- 61 **Perabo FG, Kamp S, Schmidt D et al.** Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. *Br J Cancer* 2001; **84**: 1330–8
- 62 **Loskog A, Bjorkland A, Brown MP, Korsgren O, Malmstrom PU, Totterman TH.** Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. *J Urol* 2001; **166**: 1093–7
- 63 **O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK.** Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. *J Urol* 2004; **171**: 1330–5
- 64 **Couderc B, Zitvogel L, Douin-Echinard V et al.** Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. *Cancer Gene Ther* 1998; **5**: 163–75
- 65 **Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A.** Human cancer gene therapy with cytokine gene-modified cells. *Expert Opin Biol Ther* 2004; **4**: 1595–607
- 66 **Atkins H, Davies BR, Kirby JA, Kelly JD.** Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. *Br J Cancer* 2003; **89**: 2312–9
- 67 **Novellino L, Castelli C, Parmiani G.** A listing of human tumor antigens recognized by T cells: March 2004 update. *Cancer Immunol Immunother* 2005; **54**: 187–207
- 68 **Simms MS, Hughes OD, Limb M, Price MR, Bishop MC.** MUC1 mucin as a tumour marker in bladder cancer. *BJU Int* 1999; **84**: 350–2
- 69 **Coogan CL, Estrada CR, Kapur S, Bloom KJ.** HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. *Urology* 2004; **63**: 786–90

Korespondence:
Thomas Totterman,
Clinical Immunology Division,
Department of Oncology, Radiology
and Clinical Immunology,
Rudbeck Laboratory,
Uppsala University Hospital,
S-751 85 Uppsala, Sweden.
e-mail:
thomas.totterman@klinimm.uu.se

Zkratky:

DC, dendritic cell; **NK**, natural killer;
CTL, cytolytic T lymphocyte; **TCR**, T
cell receptor; **TAA**, tumour-
associated antigen; **TLR**, toll-like
receptor; **GM-CSF**, granulocyte

macrophage-colony stimulating
factor; **T-reg**, regulatory T cell;
ODN, oligodeoxynucleotide; **TIL**,
tumour infiltrating lymphocyte;
PSMA, prostatespecific membrane
antigen; **PAP**, prostatic acid

phosphatase; **PSCA**, prostate stem
cell antigen; **TARP**, TCR alternate
reading frame protein; **hTERT**,
human telomerase reverse
transcriptase; **CIS**, carcinoma *in
situ*.